William Nguyen, MD
Allergy & Immunology · Redmond, WANPI 1861445017
Payments from drug & device makers
Across 500 payments — averaging $54.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$19K
- Sanofi$1K
- GSK$1K
- Takeda Pharmaceuticals U.S.A., Inc.$994
- Regeneron Healthcare Solutions, Inc.$813
- Grifols USA, LLC$576
- plus $4K from 30 others
What the payments were for
- Consulting fees$1090%
- Speaking & faculty fees$14,25052%
- Travel & lodging$1,1814%
- Food & beverage$11,52642%
- Education$1340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 129 | $19,020 |
| Sanofi | 49 | $1,201 |
| GSK | 57 | $1,020 |
| Takeda Pharmaceuticals U.S.A., Inc. | 51 | $994 |
| Regeneron Healthcare Solutions, Inc. | 35 | $813 |
| Grifols USA, LLC | 27 | $576 |
| Novartis | 21 | $414 |
| Pfizer | 14 | $357 |
| Biocryst US Sales Co., LLC | 12 | $323 |
| Amgen(2 entities) | 15 | $311 |
| Genentech USA, Inc. | 11 | $273 |
| Covis Pharma GmbH | 13 | $230 |
| CSL Behring | 7 | $204 |
| Pharming Healthcare, Inc. | 7 | $179 |
| Alk-abello, Inc | 4 | $177 |
| Kaleo, Inc. | 7 | $139 |
| Octapharma USA, Inc. | 5 | $114 |
| ADMA Biomanufacturing LLC | 4 | $109 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $103 |
| Shire North American Group Inc | 4 | $73 |
| Abbott | 2 | $67 |
| Boehringer Ingelheim | 4 | $58 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| AbbVie | 2 | $45 |
| Blueprint Medicines Corporation | 1 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Azurity Pharmaceuticals, Inc. | 1 | $33 |
| Ionis Pharmaceuticals, Inc. | 1 | $32 |
| Tersera Therapeutics LLC | 1 | $32 |
| Paratek Pharmaceuticals, Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $23 |
| Genentech, Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $18 |
| Bio Products Laboratory USA, Inc. | 1 | $15 |
| Cycle Pharmaceuticals Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,200 in reported general payments places this provider in the 80th percentile of 81 allergy & immunology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 24 | $113,037 |
| TezspireTezepelumab-Ekko | 13 | $54,428 |
| XolairOmalizumab | 15 | $46,680 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $38,670 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $15,003 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $7,268 |
| Arnuity ElliptaFluticasone Furoate | 17 | $7,136 |
| DuleraMometasone/Formoterol | 11 | $5,107 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 47 | $4,521 |
| Fluticasone Propionate HfaFluticasone Propionate | 17 | $2,735 |
| Epinephrine | 11 | $2,300 |
| Montelukast Sodium | 86 | $1,245 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,031 |
| Azelastine Hcl | 29 | $973 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 12 | $649 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,020 | $60,81093 claims |
| AstraZenecaTezspire | $19,020 | $54,42813 claims |
| Genentech, Inc.Xolair | $23 | $46,68015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 81 allergy & immunology providers in Washington.
Other allergy & immunology in Redmond
- Michael WeissRedmond$16K
- David ElkayamBellingham$2.1M
- Daniel PetroniSeattle$2M
- Richard GowerSpokane$1.1M
- Sanjeev JainLongview$392K
- William HendersonSeattle$296K
- Taiil SongLakewood$192K
- Mary FarringtonSeattle$176K
- Frank VirantSeattle$107K
- Leonard AltmanSeattle$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.